News

Best of 2012 Eurobiotechnews
Enlarge image

2012EU

Best of 2012 Eurobiotechnews

21.12.2012 - At the end of the year eurobiotechnews.eu presents a brief statistics on the popular articles on biotech in 2012.

Here is the ranking of our most prominent news.

1. First gene therapy in Europe approved

2. GSK aquires Cellzome

3. UCB: Positive Phase III results with Cimzia

4. Sanofi: Timeout for Campath

5. EMA changes biosimilar rules

The top 5 of 2012's most-read articles all feature topics in medicine and pharmacology. However, EuroBiotechNews also reports about new developments in industrial and agricultural biotechnology as well as research politics in general. This is reflected by the most-read articles No. 8 and No. 11. Baltic biotech attracts investors is an exclusive conference report about the first Life Science Baltics conference. Study claims GMO cancer risk picks up one of the most controversial discussion in 2012: the safety of genetically modified maize.

We hope that you will join us again in 2013 as your source of breaking biotech news.

EuroBiotechNews wishes you a Merry Christmas and a happy New Year! We will be back with daily news and a packed calendar on Wednesday 2nd January.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/best-of-eurobiotechnewseu.html

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.47 CHF27.03%
  • BIOFRONTERA2.07 EUR4.02%
  • FORMYCON17.40 EUR3.02%

FLOP

  • STRATEC BIOMEDICAL43.50 EUR-3.59%
  • MEDIGENE4.55 EUR-1.94%
  • EVONIK30.88 EUR-1.66%

TOP

  • WILEX3.15 EUR47.9%
  • CYTOS0.47 CHF38.2%
  • EVOLVA1.69 CHF18.2%

FLOP

  • MOLOGEN5.27 EUR-13.7%
  • SANTHERA97.20 CHF-11.4%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA97.20 CHF2367.0%
  • WILEX3.15 EUR416.4%
  • FORMYCON17.40 EUR126.0%

FLOP

  • CYTOS0.47 CHF-83.5%
  • MOLOGEN5.27 EUR-55.6%
  • PAION2.09 EUR-54.0%

No liability assumed, Date: 05.03.2015